Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease

Gut and Liver

Volumn 5, Issue 1, 2011, Pages 37-45

  Kato, Kyoichi ^a   Fukunaga, Ken ^a   Kamikozuru, Koji ^a   Kashiwamura, Shinichiro ^a   Hida, Nobuyuki ^a   Ohda, Yoshio ^a   Takeda, Naohisa ^a   Yoshida, Koji ^a   Iimuro, Masaki ^a   Yokoyama, Yoko ^a   Kikuyama, Risa ^a,b   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Crohn's disease; Infliximab; RANTES; Regulatory T cell; Transforming growth factor 1

Indexed keywords

CD4 ANTIBODY; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; MALE; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; REMISSION;

EID: 79952926337     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2011.5.1.37     Document Type: Article

References (36)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
2. Fiorino G, Rovida S, Correale C, Malesci A, Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? Curr Drug Targets 2010;11:249-260.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549. (Pubitemid 34621118)
4. Yokoyama Y, Fukunaga K, Fukuda Y, et al. Demonstration of lowregulatory CD25High+CD4+ and high-pro-inflammatory CD28- CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007;52:2725-2731. (Pubitemid 47373881)
5. Kamikozuru K, Fukunaga K, Hirota S, et al. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol 2009;156:320-327.
6. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
7. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 Suppl 1:i36-i58. (Pubitemid 43268292)
8. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77(4 Pt 2):829-842. (Pubitemid 9257851)
9. Matsumura K, Nakase H, Yamamoto S, et al. Modulation of the Th1/Th2 balance by infliximab improves hyperthyroidism associated with a flare-up of ulcerative colitis. Inflamm Bowel Dis 2009;15:967-968.
10. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-296. (Pubitemid 24041204)
11. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-582.
12. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205. (Pubitemid 28307304)
13. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9:641-649. (Pubitemid 351714729)
14. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
15. Kiliç ZM, Ayaz S, Ozin Y, Nadir I, Cakal B, Ulker A. Plasma transforming growth factor-beta1 level in inflammatory bowel disease. Turk J Gastroenterol 2009;20:165-170.
16. Fantini MC, Rizzo A, Fina D, et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2009;136:1308-1316, e1-e3.
17. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGFbeta are required for differentiation of human T(H)17 cells. Nature 2008;454:350-352.
18. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886. (Pubitemid 38032120)
19. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002;195:1499-1505. (Pubitemid 34602827)
20. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-1253. (Pubitemid 32703119)
21. Chamouard P, Monneaux F, Richert Z, et al. Diminution of Circulating CD4+CD25 high T cells in naïve Crohn's disease. Dig Dis Sci 2009;54:2084-2093.
22. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127. (Pubitemid 30398626)
23. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-883. (Pubitemid 28141661)
24. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-345.
25. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003;278:289-295. (Pubitemid 36043575)
26. Oki M, Ohtani H, Kinouchi Y, et al. Accumulation of CCR5+ T cells around RANTES+ granulomas in Crohn's disease: a pivotal site of Th1-shifted immune response? Lab Invest 2005;85:137-145.
27. Freeman HJ. Granuloma-positive Crohn's disease. Can J Gastroenterol 2007;21:583-587.
28. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279.
29. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004;15:353-366. (Pubitemid 39140699)
30. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376-392. (Pubitemid 40431090)
31. Powrie F, Read S, Mottet C, Uhlig H, Maloy K. Control of immune pathology by regulatory T cells. Novartis Found Symp 2003;252:92-98.
32. Liu H, Hu B, Xu D, Liew FY. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003;171:5012-5017. (Pubitemid 37432781)
33. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-1878. (Pubitemid 40824698)
34. Singh B, Read S, Asseman C, et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001;182:190-200. (Pubitemid 33070218)
35. Sitohy B, Hammarström S, Danielsson A, Hammarström ML. Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action. Clin Exp Immunol 2008;151:326-333.
36. Fahlén L, Read S, Gorelik L, et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 2005;201:737-746. (Pubitemid 40395119)